[
  {
    "symbol": "VERA",
    "timestamp": "2025-01-03 17:18:25",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's\u00a0product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/dmVyYXR4LmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/dmVyYXR4LmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "price": 43.22,
    "priceChange": 2.4170616113743977,
    "openPrice": 42.72,
    "prevClose": 42.2,
    "dayHigh": 43.69,
    "dayLow": 42.6275,
    "volume": 296409,
    "prevVolume": 368575,
    "volumeMetrics": {
      "recentVolumes": [
        527067,
        446780,
        368575,
        296409
      ],
      "volumeDates": [
        "2024-12-29",
        "2024-12-30",
        "2025-01-01",
        "2025-01-02"
      ],
      "dailyChanges": [
        -15.23,
        -17.5,
        -19.58
      ],
      "averageVolume": 718506.2419354839,
      "volumeChange": -19.58,
      "volumeVsAvg": -58.75
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 718506.2419354839
    },
    "fiftyTwoWeekHigh": 51.61,
    "fiftyTwoWeekLow": 14.2,
    "highProximityPct": 16.256539430342958,
    "marketCap": 2736822350.66,
    "insiderActivity": {
      "recent_trades": 14,
      "net_shares": 95661,
      "notable_trades": [
        {
          "date": "2024-12-19",
          "insider": "FORDYCE MARSHALL",
          "position": "Chief Executive Officer",
          "type": "Stock Award",
          "shares": 75161,
          "value": 217726.0,
          "price_per_share": 2.896794880323572
        },
        {
          "date": "2024-12-18",
          "insider": "FORDYCE MARSHALL",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 17500,
          "value": 753680.0,
          "price_per_share": 43.06742857142857
        },
        {
          "date": "2024-12-11",
          "insider": "FORDYCE MARSHALL",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 17500,
          "value": 821523.0,
          "price_per_share": 46.94417142857143
        },
        {
          "date": "2024-11-25",
          "insider": "FORDYCE MARSHALL",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 19375,
          "value": 929560.0,
          "price_per_share": 47.97729032258064
        },
        {
          "date": "2024-11-13",
          "insider": "FORDYCE MARSHALL",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 30625,
          "value": 1516037.0,
          "price_per_share": 49.50324897959184
        },
        {
          "date": "2024-10-28",
          "insider": "SEIDENBERG BETH C",
          "position": "Director",
          "type": "Sale",
          "shares": 15000,
          "value": 720493.0,
          "price_per_share": 48.03286666666666
        },
        {
          "date": "2024-10-23",
          "insider": "FORDYCE MARSHALL",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 19375,
          "value": 782610.0,
          "price_per_share": 40.392774193548384
        },
        {
          "date": "2024-10-09",
          "insider": "FORDYCE MARSHALL",
          "position": "Chief Executive Officer",
          "type": "Sale",
          "shares": 15625,
          "value": 597568.0,
          "price_per_share": 38.244352
        }
      ],
      "summary": {
        "total_sales": 135000,
        "total_purchases": 53000,
        "total_awards": 177661,
        "sales_count": 7,
        "purchases_count": 1,
        "awards_count": 6,
        "total_value": {
          "sales": 6121471.0,
          "purchases": 0.0,
          "awards": 514648.0
        }
      },
      "latest_date": "2024-12-19"
    },
    "recentNews": [
      {
        "title": "Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-12-09T23:29:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/12/09/2994136/0/en/Vera-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "type": "VERA"
      },
      {
        "title": "Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-28T21:37:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/28/2970400/0/en/Vera-Therapeutics-Announces-Proposed-Public-Offering-of-Class-A-Common-Stock.html",
        "type": "VERA"
      },
      {
        "title": "Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-10-26T23:30:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/10/26/2969705/0/en/Vera-Therapeutics-Announces-96-week-eGFR-Stabilization-in-ORIGIN-Phase-2b-Study-of-Atacicept-in-IgAN-in-a-Late-Breaking-Oral-Presentation-at-the-American-Society-of-Nephrology-Kidn.html",
        "type": "VERA"
      },
      {
        "title": "Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-07-05T20:31:33Z",
        "url": "https://www.globenewswire.com/news-release/2024/07/05/2909190/0/en/Vera-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "type": "VERA"
      },
      {
        "title": "Vera Therapeutics Appoints Christy J. Oliger to Board of Directors",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-06-11T20:01:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/06/11/2897152/0/en/Vera-Therapeutics-Appoints-Christy-J-Oliger-to-Board-of-Directors.html",
        "type": "VERA"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -15.614444
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [
          0.0,
          0.0,
          0.0,
          0.0
        ],
        "revenueChanges": [
          null,
          null,
          null,
          null
        ],
        "netIncome": [
          -95990000.0,
          -89056000.0,
          -32609000.0,
          -53413000.0
        ],
        "netIncomeChanges": [
          null,
          null,
          null,
          null
        ],
        "operatingMargin": [
          0,
          0,
          0,
          0
        ],
        "operatingMarginChanges": [
          null,
          null,
          null,
          null
        ],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": [
          "2023-12-31",
          "2022-12-31",
          "2021-12-31",
          "2020-12-31"
        ]
      }
    },
    "alerts": 2,
    "alertDetails": {
      "priceAlert": false,
      "volumeSpike10": false,
      "volumeSpike20": false,
      "highVolume": false,
      "insiderAlert": true,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  },
  {
    "symbol": "INMB",
    "timestamp": "2025-01-03 17:18:28",
    "sector": "Healthcare",
    "industry": "Biotechnology",
    "description": "INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.",
    "branding": {
      "icon_url": "https://api.polygon.io/v1/reference/company-branding/aW5tdW5lYmlvLmNvbQ/images/2024-10-01_icon.jpeg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq",
      "logo_url": "https://api.polygon.io/v1/reference/company-branding/aW5tdW5lYmlvLmNvbQ/images/2024-10-01_logo.svg?apiKey=WL7rkKMQGlEpcRy_GogYH6hyclU8sOnq"
    },
    "price": 5.295,
    "priceChange": 7.403651115618666,
    "openPrice": 5.01,
    "prevClose": 4.93,
    "dayHigh": 5.42,
    "dayLow": 5.01,
    "volume": 408471,
    "prevVolume": 268625,
    "volumeMetrics": {
      "recentVolumes": [
        242309,
        213611,
        268625,
        408471
      ],
      "volumeDates": [
        "2024-12-29",
        "2024-12-30",
        "2025-01-01",
        "2025-01-02"
      ],
      "dailyChanges": [
        -11.84,
        25.75,
        52.06
      ],
      "averageVolume": 218867.2741935484,
      "volumeChange": 52.06,
      "volumeVsAvg": 86.63
    },
    "technicals": {
      "rsi": null,
      "volumeSMA": 218867.2741935484
    },
    "fiftyTwoWeekHigh": 14.74,
    "fiftyTwoWeekLow": 4.32,
    "highProximityPct": 64.07734056987789,
    "marketCap": 117403128.045,
    "insiderActivity": {
      "recent_trades": 0,
      "net_shares": 0,
      "notable_trades": [],
      "summary": {
        "total_sales": 0,
        "total_purchases": 0,
        "total_awards": 0,
        "sales_count": 0,
        "purchases_count": 0,
        "awards_count": 0
      }
    },
    "recentNews": [
      {
        "title": "Inmune Bio re-elects directors, ratifies auditor - Investing.com",
        "publisher": "Investing.com",
        "timestamp": "2024-07-19T21:53:47Z",
        "url": "https://www.investing.com/news/company-news/inmune-bio-reelects-directors-ratifies-auditor-93CH-3527788",
        "type": "INMB"
      },
      {
        "title": "Zura Bio initiates exchange offer for warrants By Investing.com - Investing.com",
        "publisher": "Investing.com",
        "timestamp": "2024-07-12T11:37:58Z",
        "url": "https://www.investing.com/news/company-news/elevai-labs-amends-license-agreement-with-inmune-bio-93CH-3517109",
        "type": "ELAB"
      },
      {
        "title": "INmune Bio Inc. to Join Russell 3000\u00ae Index",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-30T12:00:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/30/2890678/0/en/INmune-Bio-Inc-to-Join-Russell-3000-Index.html",
        "type": "INMB"
      },
      {
        "title": "INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-05-09T20:05:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/05/09/2879206/0/en/INmune-Bio-Inc-Announces-First-Quarter-2024-Results-and-Provides-Business-Update.html",
        "type": "INMB"
      },
      {
        "title": "INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update",
        "publisher": "GlobeNewswire Inc.",
        "timestamp": "2024-03-28T20:01:00Z",
        "url": "https://www.globenewswire.com/news-release/2024/03/28/2854450/0/en/INmune-Bio-Inc-Announces-Year-End-2023-Results-and-Provides-a-Q4-Business-Update.html",
        "type": "INMB"
      }
    ],
    "fundamentals": {
      "peRatios": {
        "trailingPE": null,
        "forwardPE": -2.590509
      },
      "estimates": {
        "revenue": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        },
        "earnings": {
          "nextQuarter": null,
          "currentYear": null,
          "nextYear": null
        }
      },
      "quarterlyMetrics": {
        "revenue": [],
        "revenueChange": [],
        "periods": []
      },
      "detailedQuarterly": {
        "revenue": [
          155000.0,
          374000.0,
          181000.0,
          11000.0
        ],
        "revenueChanges": [
          null,
          null,
          null,
          null
        ],
        "netIncome": [
          -30008000.0,
          -27299000.0,
          -30340000.0,
          -12099000.0
        ],
        "netIncomeChanges": [
          null,
          null,
          null,
          null
        ],
        "operatingMargin": [
          -19187.74,
          -6938.77,
          -16106.63,
          -111163.64
        ],
        "operatingMarginChanges": [
          null,
          null,
          null,
          null
        ],
        "freeCashFlow": [],
        "freeCashFlowChanges": [],
        "dates": [
          "2023-12-31",
          "2022-12-31",
          "2021-12-31",
          "2020-12-31"
        ]
      }
    },
    "alerts": 4,
    "alertDetails": {
      "priceAlert": true,
      "volumeSpike10": true,
      "volumeSpike20": true,
      "highVolume": true,
      "insiderAlert": false,
      "newsAlert": true,
      "technicalAlert": null,
      "nearHighAlert": false
    }
  }
]